Skip to main content
. 2014 Jul 28;111(32):E3316–E3324. doi: 10.1073/pnas.1406123111

Fig. 5.

Fig. 5.

Combined targeting of MYC and β-catenin prevents tumor recurrence. (A) MYC lymphoma cells expressing LUC2 and DD-ICAT were transplanted s.c. into SCID recipients. Bioluminescence signal was quantified over time after initiation of treatment to inactivate MYC (+DOX), β-catenin (+TMP), or both MYC and β-catenin (+DOX/TMP). Values are means ± SEM (DD-ICAT +DOX, n = 7; DD-ICAT +TMP, n = 3; DD-ICAT +DOX/TMP, n = 5). (B) Representative bioluminescence images of tumor-bearing mice at 0, 8, and 24 (+TMP, +DOX/TMP) or 26 (+DOX) d after initiation of treatment. (C) Recurrence-free survival of mice transplanted with MYC lymphomas and treated with DOX, TMP, or both DOX and TMP as in A. Tumors were scored as recurrences on the day when the bioluminescence signal increased after initial tumor regression. Survival curves were compared by the log-rank test. (D) Quantification of minimum residual disease in transplanted mice treated with DOX, TMP, or both DOX and TMP. Values are means ± 95% CIs. *P < 0.05, **P < 0.01, ***P < 0.001.